


Massachusetts

In less than a decade, Bristol Myers Squibb has become a leading life sciences presence in Massachusetts. Our workforce has the agility and creativity of an entrepreneurial biotech while being bolstered by the extensive resources and expertise of our global network.



Bristol Myers Squibb currently has two state-of-the-art facilities in Massachusetts: a R&D research center in **Cambridge** and a cell therapy and biologics development and manufacturing site in **Devens**. The company’s talent base in the state encompasses world-class scientists and a skilled workforce underpinning an advanced manufacturing operation supporting the company vision to transform

Areas of Focus

In **Cambridge**, our state-of-the-art facility at Cambridge Crossing brings together dynamic discovery and development teams – from discovery to chemistry to informatics and predictive sciences – to work smarter and faster toward our vision of transforming patients’ lives through science.

Built with end-to-end R&D in mind, the integrated lab and workspace creates opportunities for scientists to forge meaningful collaborations, advance scientific discovery and accelerate development of new medicines.

From translational medicine to clinical pharmacology, our molecular invention engine brings together experts across small molecule drug discovery, biotherapeutics and cell therapy to invent new treatments for the future across three thematic research centers:

- Our Mechanisms of Cancer Resistance (MoCR) Thematic Research Center (TRC) investigates novel ways to precisely address cancer-specific vulnerabilities and enhance or restore the body’s ability to eliminate disease, through discovering molecular mechanisms of resistance and developing medicines to address this biology.
- Within our Immunology and Cardiovascular Thematic Research Center (ICVTRC) teams in Cambridge focus on developing transformative medicines that help to suppress inflammation, reset the immune system and promote overall balance in the immune response.
- Scientists in our Neuroscience TRC pursue are building upon our leadership in protein homeostasis, immunology and inflammation to inform our development of transformational therapeutics for people with neurodegenerative, neuroinflammatory and neuromuscular diseases. This work is focused on areas of high unmet need in both common diseases like Alzheimer’s disease and rare diseases such as ALS.

The **Devens** site encompasses an established center of excellence supporting development, testing and manufacturing of biologics medicines as well as cell therapy manufacturing. Teams are responsible for developing the processes for creating complex molecule biologics as well as the clinical and commercial manufacturing for the entire biologics portfolio. In addition, a new cell therapy facility integrates the latest manufacturing equipment and impactful digital technology to help deliver personalized cell therapies to patients with aggressive hematological cancers.

Scientific and Corporate Investments

	Jobs	Bristol Myers Squibb provides high-quality jobs for residents across the state and currently employs over 2,000 people * in Massachusetts, with a total Massachusetts payroll of approximately \$325 million. <small>*As of July 2023</small>
	Investments	In 2022, economic investment in a wide range of local businesses through vendor relationships totaled over \$773 million in Massachusetts.
	Clinical Trials	Bristol Myers Squibb conducted activities to support 132 clinical trials at over 281 study sites in Massachusetts in 2022.

Making a Difference at Work and in the Community

Our commitment to Massachusetts means working to support and strengthen the communities in which we work and live.

 **Local Community Support**
We support programs, initiatives and organizations such as Community Servings, MassBioEd and Boston Healthcare for the Homeless that help improve health, expand research opportunities, promote and expand STEM education and deliver basic human services to our communities.

 **Corporate and Community Giving**
In 2023, Bristol Myers Squibb announced \$10 million in grants to 17 U.S. organizations focused on addressing social determinants of health, including healthcare access and literacy to help close gaps and increase access to healthcare.

 **Focus on Patients**
Bristol Myers Squibb helps patients through product donations to independent charitable organizations, including the Bristol Myers Squibb Patient Assistance Foundation, an independent nonprofit that assists financially needy patients who are uninsured or underinsured.
In the U.S. grants were awarded totaling \$11.2 million in 2022.

 **Global Inclusion and Diversity**
Bristol Myers Squibb has made measurable progress against its goal to award \$150 million to address health disparities: Nearly \$100 million in distributed funding has reached more than 10 million people through programs and services.

 **Supplier Diversity**
Bristol Myers Squibb's supplier diversity program is centered around an ethos of Partnering with Purpose. The organization exists to champion economic empowerment, wealth creation and job creation in the community, while fostering inclusive innovation and a supply chain that reflects the company’s values, its patients and the world.

 **Protecting the Environment**
As we experienced significant business growth, our company also has been able to reduce operation-generated greenhouse gas emissions by more than 20% and water use by more than 10% over our 2015 baselines. We are committed to running on 100% renewable electricity by 2030.

 **Product Donation**
Bristol Myers Squibb helps patients through product donations to independent charitable organizations, including the Bristol Myers Squibb Patient Assistance Foundation, an independent non-profit that assists patients financially who are uninsured or underinsured.